<DOC>
	<DOCNO>NCT02580279</DOCNO>
	<brief_summary>The investigator conduct phase II study EGCG therapy protection skin damage induce radiotherapy breast cancer . In order observe effectiveness EGCG , investigator utilize clinician assessment patient self-assessments . Physician 's skin assessment score utilizing Radiation Therapy Oncology Group ( RTOG ) score . Patient report symptom score adapt Skin Toxicity Assessment Tool ( STAT ) pain , burning , itch , pull , tenderness treatment area . The scale translate Chinese guide Chinese develop instruct use scale perform assessment .</brief_summary>
	<brief_title>Study Epigallocatechin-3-gallate ( EGCG ) Skin Prevention Patients With Breast Cancer Receiving Adjuvant Radiotherapy</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<criteria>Age â‰¥ eighteen year Eastern Cooperative Oncology Group performance status 01 Normal hematologic , hepatic function renal value Forced expiratory volume 1 &gt; 800 cc The presence rash unhealed wound radiation field A know allergy hypersensitivity EGCG Pregnancy lactation History of/current connective tissue disorder Prior radiation thorax</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Breast Neoplasms</keyword>
	<keyword>prevention &amp; control</keyword>
	<keyword>Epigallocatechin gallate</keyword>
	<keyword>Dermatitis</keyword>
</DOC>